1. TP53 Gene Mutations in Canine Osteosarcoma
- Author
-
Erik Teske, Gerard R. Rutteman, Jolle Kirpensteijn, and Marja Kik
- Subjects
Male ,Pathology ,medicine.medical_specialty ,040301 veterinary sciences ,Bone Neoplasms ,Kaplan-Meier Estimate ,Gene mutation ,medicine.disease_cause ,Polymerase Chain Reaction ,Canine Osteosarcoma ,Disease-Free Survival ,0403 veterinary science ,03 medical and health sciences ,Dogs ,0302 clinical medicine ,Polymorphism (computer science) ,Gene expression ,Biomarkers, Tumor ,medicine ,Animals ,Point Mutation ,Dog Diseases ,Gene ,Polymorphism, Single-Stranded Conformational ,Neoplasm Staging ,Osteosarcoma ,Mutation ,General Veterinary ,business.industry ,Point mutation ,04 agricultural and veterinary sciences ,Alkaline Phosphatase ,Genes, p53 ,medicine.disease ,Primary tumor ,3. Good health ,Treatment Outcome ,030220 oncology & carcinogenesis ,Cancer research ,Female ,business - Abstract
Objective— To investigate mutations of the TP53 gene in canine osteosarcoma (OS). Study Design— Clinical historic cohort study. Animals— Client-owned dogs. Methods— OS (n=59) were screened for mutations of the complete TP53 gene using polymerase chain reaction and the mutation was analyzed by single-strand conformational polymorphism. Clinical outcome of dogs with TP53-mutated OS were compared with dogs with OS without a mutation after complete surgical excision of the primary tumor. Results— TP53 gene mutations were observed in 24 of 59 (40.7%) OS; 3 mutated OS had 2 mutations. The alterations consisted mainly of point mutations (74%). Dogs with mutated OS had a significantly shorter survival time (ST) after surgery than dogs with normal tumor TP53 gene expression (P=.03). Other significant prognosticators for ST and disease-free interval included elevated serum alkaline phosphatase (P
- Published
- 2008
- Full Text
- View/download PDF